ArticleJournal for immunotherapy of cancer2021

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.

Bilal A Siddiqui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.